New Targeted Radiation Therapy Demonstrates Remarkable Results in Rare Cancer Trial
DUSSELDORF,GERMANY - A novel targeted radiation therapy using yttrium-90 (Y-90) fibroblast activation protein inhibitor (FAPI)-46 has shown promising results in a small study of patients with solitary fibrous tumors (SFTs),a rare and often aggressive cancer. The findings, presented by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), reveal that three patients achieved a near-complete response after undergoing treatment with the innovative approach.
Solitary fibrous tumors, classified as soft tissue sarcomas, typically present as benign growths, but 15% to 20% are malignant and carry a poor prognosis. Existing treatment options are limited, making this research a potential breakthrough for individuals facing advanced SFT. The study focused on patients who had previously exhausted standard therapies and exhibited high levels of the FAP protein within their tumors.
Researchers at the West German cancer Center at University Hospital Essen administered four cycles of Y-90 FAPI-46 to the three patients. Subsequent evaluation using F-18 FDG and gallium-68 FAPI-46 PET/CT scans demonstrated significant tumor reduction.
“This is the first time we have seen such strong and deep responses in advanced SFT using this precision radiation approach,” stated Dr. Rainer Hamacher of the West German Cancer Center.
The therapy leverages the FAP protein, which is often highly expressed in SFTs, to deliver targeted radiation directly to the tumor cells, minimizing damage to surrounding healthy tissue.The full news release and study details are available on the SNMMI website.
